According to the latest report by IMARC Group, titled “Kidney Cancer Therapeutics and Diagnostics Market Report by Component (Drugs, Diagnostics), Cancer Types (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, and Others), Application (Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others), and Region 2024-2032,” the global kidney cancer therapeutics and diagnostics market size reached US$ 5.1 Billion in 2023. Kidney cancer, also known as renal cancer, is diagnosed through a combination of medical history assessment, physical examination, and tests like computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET). It can also be diagnosed through biopsy and blood and urine tests. Besides this, its therapeutics encompass a range of treatment options aimed at managing and combating the growth of cancerous cells. It includes various therapies and surgeries, such as radical or partial nephrectomy, which help remove the tumor and affected kidney tissue. Additionally, kidney cancer therapeutics and diagnostics are used for removing cancer cells, controlling the spread, destroying tumors, and assisting physicians in planning treatments.
Global Kidney Cancer Therapeutics and Diagnostics Market Trends:
The increasing prevalence of kidney cancer worldwide due to the aging population, lifestyle factors like smoking and obesity, and genetic predisposition represent one of the key factors driving the market. Additionally, the rising awareness among individuals about kidney cancer symptoms and the importance of early detection and treatment are catalyzing the demand for kidney cancer therapeutics and diagnostics. Apart from this, the increasing use of genomic and personalized medicine for effective treatment approaches is contributing to the market growth. Furthermore, governing agencies of several countries are introducing awareness campaigns and healthcare programs, which is offering a favorable market outlook. Moreover, advancements in targeted therapies, immunotherapies, and personalized medicine and the development of more advanced diagnostic technologies, like novel imaging methods, liquid biopsies, genomic testing, and artificial intelligence (AI)-driven diagnostic tools, are propelling the market growth. Besides this, a rise in the improvement of healthcare infrastructure and facilities are positively influencing the market. Looking forward, the market value is projected to reach US$ 8.8 Billion by 2032, expanding at a CAGR of 6.22% during 2024-2032.
Market Summary:
- Based on the component, the market has been bifurcated into drugs [drugs by therapeutic class {targeted therapy, immunotherapy, and others} and drugs by pharmacological class {angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2)}] and diagnostics [imaging test, biopsy, blood test, and others]. Drugs currently dominate the market, holding the largest share.
- On the basis of the cancer types, the market has been divided into clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. Clear cell RCC represents the largest market segment.
- Based on the application, the market has been divided into hospitals, pharmaceutical labs, genomic laboratories, and others. At present, hospitals exhibit a clear dominance in the market.
- Region-wise, the market has been categorized into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
- The competitive landscape of the market has also been examined, with some of the key players being Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, and Pfizer Inc.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Components Covered |
- Drugs: Drugs by Therapeutic Class, Drugs by Pharmacologic Class
- Diagnostics: Imaging Test, Biopsy, Blood Test, Others
|
Cancer Types Covered |
Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, Others |
Applications Covered |
Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others |
Regions Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800